Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Seventeen white patients from the Stanford Sleep Disorders Clinic complaining of excessive daytime somnolence (EDS) were selected for restriction-fragment-length polymorphism (RFLP) studies. Fourteen of the patients with clinically diagnosed narcolepsy were seropositive for DR2. RFLP analysis of these patients compared with a homozygous DR2-Dw2 cell line failed to reveal any polymorphism when digested with six restriction endonucleases and hybridized with three different cDNA probes. None of the three patients with central nervous system hypersomnia, a syndrome similar to narcolepsy, were DR2-positive. We conclude that any polymorphism of the DR beta, DQ alpha, or DQ beta genes of DR2 narcoleptics that might distinguish them from DR2 normals cannot be resolved through RFLP analysis.

Original publication

DOI

10.1002/jnr.490180134

Type

Journal article

Journal

Journal of neuroscience research

Publication Date

01/1987

Volume

18

Pages

239 - 244

Addresses

Department of Medical Microbiology, Stanford University School of Medicine, California.

Keywords

Humans, Narcolepsy, HLA-D Antigens, HLA-DR Antigens, HLA-DR2 Antigen, Major Histocompatibility Complex, Polymorphism, Genetic, Polymorphism, Restriction Fragment Length